Five cancer cells were injected subcutaneously into the dorsal region near the thigh of mouse. Tumor growth is monitored weekly by an IVIS Spectrum. The tumor was visible 28 days post implantation; […]
[Video Profile] Interview with Craig Davenport, President & CEO of Endocare
Each year over 234,000 new cases of prostate cancer are diagnosed in the U.S. Treatment options include surgery, radiation therapy, hormone therapy, “watchful waiting” and cryotherapy. Treatment depends on factors including the […]
Painting the Colon: Early Stage Cancer Detection without Biopsy
Most cases of colon cancer begin as small noncancerous polyps. Over time these polyps may become colon cancers. Regular screening helps identify polyps before they become cancerous, allowing for prophylactic treatment. According […]
[Video Profile] Interview with Ron Andrews, President & CEO of Clarient
Clarient provides access to technologies and services for the characterization, assessment and treatment of cancer. The company offers a full range of diagnostic technologies and services for the clinical cancer diagnostics industry […]
Expanded Indications for Immunicon’s CellSearch
Immunicon’s CellSearch Circulating Tumor Cell (CTC) Kit has received FDA clearance as an aid in the monitoring of patients with metastatic prostate cancer. The kit is now cleared for three of the […]
HemeScan: CombiMatrix and Clarient to Advance Personalized Therapies for Chronic Lymphotic Leukemia
More partnering news, this time from CombiMatrix and Clarient, who will market and sell a genomics-based cancer test called HemeScan. HemeScan was developed by CombiMatrix; the test forecasts the probable outcome of […]
A Filtration Collaboration: Delcath and Aethlon to Expand Cancer Treatment Options
Aethlon Medical and Delcath Systems have agreed to jointly research and develop a new filtration cartridge for use in Delcath’s percutaneous hepatic perfusion (“PHP”) system. PHP is a technology designed to isolate […]
New Study Highlights Promising Gene-Based Predictor of Prostate Cancer Risk
Test to be commercialized by Proactive Genomics, LLC In the past few years, novel research tools have emerged which scientist to systematically and objectively evaluate genetic variants in the genome. These new […]
